Published Date : 04 May 2023
The global non-opioid pain treatment industry revenue will touch around USD 79.7 billion by 2032 from USD 42.3 billion in 2022 and is growing at a CAGR of 6.54% between 2023 and 2032.
The industry's growth may be attributed to the top businesses' rising R&D spending for the development of novel non-opioid analgesic drugs as well as the initiatives of both public and private organizations to create helpful programs and increase awareness of the treatments that are offered.
Several Americans are suffering. Some people have back discomfort or recurring headaches, while others are healing after surgery, injuries sustained in sports, or mishaps. Millions of prescriptions for painkillers are made each year, many of which are for potent opioids that can have negative effects and encourage addiction. Aspirin, ibuprofen, and acetaminophen are all non-opioid painkillers that are available over-the-counter and on prescription, along with massage therapy, acupuncture, and high-tech procedures that use radio waves and electrical impulses.
Increasing acceptance of non-opioid painkiller patches, which, when used gradually over an extended period of time, provide a reduced risk of addiction than fentanyl patches.
An aging population, a rising need for healthcare treatment advancements, and an increase in ailments associated with contemporary lifestyles are all contributing to the growth of the non-opioid pain medication industry.
The industry for non-opioid pain management is growing as a consequence of increased research and development spending, involvement in clinical trials, and improvements to the regulatory environment.
In terms of revenue share in 2022, North America had the majority of positions in the non-opioid pain management industry with 45.23%. High NSAID demand, strong government efforts to reduce opioid usage, advancements in the healthcare system's infrastructure, and the existence of significant players are all factors contributing to this dominance.
The Asia Pacific non-opioid pain treatment industry is anticipated to expand at a rapid rate over the course of the forecast period as a result of factors including an increase in the patient population, increased government initiatives in the healthcare industry, an increase in the incidence of diseases like cancer, arthritis, and dental disorders, as well as an increase in the population of geriatrics and key players' growing interest in setting up shop in the area.
Non-opioid Pain Treatment Industry Report Scope:
|Market Revenue in 2023||USD 45.07 Billion|
|Projected Forecast Revenue in 2032||USD 79.7 Billion|
|Growth Rate from 2023 to 2032||CAGR of 6.54%|
|Largest Market||North America|
|Forecast Period||2023 to 2032|
|Regions Covered||North America, Europe, Asia-Pacific, Latin America and Middle East & Africa|
Drivers: Low cost and lack of adverse effects
The demand for non-opioid pain medicine is rising due to these medications' simplicity and effectiveness, as well as certain therapies' low cost and lack of adverse effects.
The risks of nausea and vomiting, sleepiness, androgen shortage, respiratory depression, constipation, physical dependency, and tolerance are only a few of the drawbacks of opioids. Also, there is a chance that patients or non-medical users will abuse or get addicted to opioid drugs. For these reasons, it is good to think about alternatives to opiate painkillers. As a result, the industry for non-opioid pain relief is expanding globally.
The main elements driving the expansion of non-opioid pain management include improved healthcare facilities, the availability of sophisticated and new treatment choices, and rising research and development initiatives in this area.
Restraints: Inadequate knowledge
The general population favors alternative treatments due to a lack of knowledge and an industry filled with counterfeit items. Even non-opioid medicines lack the required long-term effectiveness. These are the typical barriers to industry growth.
There are several pharmacological and non-pharmacological pain management strategies available to therapists today. Opioids can speed up healing and recovery for some people with acute, severe pain. Opioids offer pain relief and enable individuals with different types of severe chronic pain to go about their everyday lives.
Healthcare providers are carefully evaluating all available alternatives, from opioids and non-opioid analgesics to mind-body therapies, and weighing their potential benefits against their risks as the medical community focuses more on safer, more prudent opioid prescribing and reducing opioid misuse. Clinicians will have more proof of non-opioid analgesics' efficacy when further research and trials are conducted.
Drug Class Insights:
In 2022, the nonsteroidal anti-inflammatory drug (NSAID) industry category has been in the lead. The industry is anticipated to maintain its dominance during the anticipated period due to the wide availability of inexpensive, efficient NSAID medications and safer treatment choices than opioids. The continued dominance during the projection period is also impacted by advancements in drug formulation and increased use of novel medications.
Pain Type Insights:
The chronic pain segment dominated the industry in 2022 as a result of the rising prevalence of chronic pain, including neuropathic pain and pain caused by inflammatory diseases like osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and others, as well as the rising demand for non-opioid analgesic medications. It is estimated that the other category would have profitable growth throughout the course of the projected time. The increase in accidental or unintentional injuries as well as acute pain is to blame for the segment's growth.
Route of Administration Insights:
The oral segment dominated the industry in 2022 due to the approval and release of innovative oral NSAIDs for pain management. Advil comes in oral tablet form and is prescribed to treat a range of ailments, including headaches, menstrual cramps, toothaches, and muscle aches.
The injectable industry is anticipated to grow at the fastest rate during the forecast period, 9.3%, as a result of factors like technological advancements in drug administration, the introduction of novel IV products, and the increased usage of local anesthetic products for surgical procedures.
Distribution Channel Insights:
The retail pharmacy sector dominated the non-opioid pain treatment industry in 2022 as a result of the broad accessibility of non-opioid analgesic drugs and customers' straightforward access to pharmaceuticals. The primary retail pharmacies that sell non-opioid analgesics are Walgreens Boots Alliance, Inc., CVS Health, Ahold Delhaize, Rite Aid Corporation, and Albertsons Companies, Inc. The hospital pharmacy industry will come in second in 2022 in terms of revenue. This is related to the widespread use of non-opioid analgesics in the treatment of hospitalized patients.
Major Key Players:
By Drug Class
By Pain Type
By Route of Administration
By Distribution Channel
Buy this Research Report@ https://www.precedenceresearch.com/checkout/2616
You can place an order or ask any questions, please feel free to contact at firstname.lastname@example.org | +1 9197 992 333